We have added some new comedications to the interaction checker and revised a few existing interactions.
Four new comedications have been added – zolmitriptan (Anti-migraine), brentuximab vedotin (Cancer therapies), enzalutamide (Cancer therapies) and polatuzumab vedotin (Cancer therapies). Cabergoline has been split into two entries – one for the treatment of Parkinson’s disease (Parkinsonism agents) and one for lactation suppression (Other).
We have revised the interactions for rilpivirine (and rilpivirine containing STRs) with the azole antifungals fluconazole, itraconazole, ketoconazole, posaconazole and voriconazole. These have changed from amber to yellow as the risk of a fungal infection breakthrough is considered low when using the standard dose of rilpivirine. Interactions for bictegravir with bosentan and modafinil have been changed from yellow to amber to bring them in line with other moderate CYP3A4 inducers.
These updates are available on the interaction checker and iChart app and new PDF files have been uploaded to the Prescribing Resources section of the website.
